Received Nov 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (DAPTACEL) | SANOFI PASTEUR | UNK | 3CA20C1 | OT |
| TDAP | TDAP (ADACEL) | SANOFI PASTEUR | UNK | — | OT |
gave DAPTACEL when they were supposed to give ADACEL to a 12-year-old fully vaccinated patient, with no reported adverse event; gave DAPTACEL when they were supposed to give ADACEL to a 12-year-old fully vaccinated patient, with no reported adverse event; Initial information received on 24-Oct-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 12 years old and unknown gender patient who received diphtheria-15/tetanus/5 AC pertussis vaccine [Daptacel] when they were supposed to give diphtheria-2/tetanus/5 AC pertussis vaccine [Adacel] to a fully vaccinated patient, with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 22-Oct-2025, the patient received an unknown dose of diphtheria-15/tetanus/5 AC pertussis vaccine Suspension for injection (strength- unknown, expiry date- 28-FEB-2026 and lot 3CA20C1) via unknown route in unknown administration site for Immunization when they were supposed to give diphtheria-2/tetanus/5 AC pertussis vaccine Suspension for injection (strength, expiry date and lot number not reported) for prophylactic vaccination (Immunization) to a fully vaccinated patient, with no reported adverse event (wrong product administered) (product administered to patient of inappropriate age) (latency- same day). Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.